The Filings Report

Quest Diagnostics Inc.

DGXNYSECIK 1022079Healthcare / Healthcare Providers & Servicesfiscal year ends December74 quarters since 2008

Revenue, Q3 FY2026
$3.1B
+10.0% on Q3 FY2025
Net income
$312M
+27.3% on Q3 FY2025
Free cash flow
$445M
+6.2% on Q3 FY2025
Diluted EPS
$2.78
+28.7% on Q3 FY2025
Revenue, TTM
$11.8B
trailing four quarters
Net margin, TTM
9.5%
net income $1.1B
Free cash flow, TTM
$1.4B
$2.0B less $576M capex
Cash and equivalents
$797M
long-term debt $5.5B, Sep 30, 2026
Shares, 12-month change
−1.1%
110M shares, Sep 30, 2026
Buybacks, TTM
—
no yield
Dividends, TTM
$369M
1.3% of market value
Market value
$27.7B
at the close, buybacks

Latest quarter Q3 FY2026, filed October 23, 2026. Trailing figures sum the latest four quarters. Market values at the latest close, from a market data vendor.

In Q3 FY2026, the quarter ended September 30, 2026, Quest Diagnostics Inc. reported revenue of $3.1B, +10.0% on Q3 FY2025, and net income of $312M (+27.3%). Operating margin was 15.5%. Free cash flow, operating cash flow less capital expenditures, was $445M ($611M less $166M). Diluted earnings per share were $2.78.

The last 16 quarters

Q4 FY2022 to Q3 FY2026, through the filing of October 23, 2026.

Revenue and net incomeRevenueNet income
$0$1B$2B$3B$4BQ4'22, Revenue: $2.3BQ4'22, Net income: $101MQ4'22Q1'23, Revenue: $2.3BQ1'23, Net income: $202MQ1'23Q2'23, Revenue: $2.3BQ2'23, Net income: $235MQ2'23Q3'23, Revenue: $2.3BQ3'23, Net income: $225MQ3'23Q4'23, Revenue: $2.3BQ4'23, Net income: $192MQ4'23Q1'24, Revenue: $2.4BQ1'24, Net income: $194MQ1'24Q2'24, Revenue: $2.4BQ2'24, Net income: $229MQ2'24Q3'24, Revenue: $2.5BQ3'24, Net income: $226MQ3'24Q4'24, Revenue: $2.6BQ4'24, Net income: $222MQ4'24Q1'25, Revenue: $2.7BQ1'25, Net income: $220MQ1'25Q2'25, Revenue: $2.8BQ2'25, Net income: $282MQ2'25Q3'25, Revenue: $2.8BQ3'25, Net income: $245MQ3'25Q4'25, Revenue: $2.8BQ4'25, Net income: $245MQ4'25Q1'26, Revenue: $2.9BQ1'26, Net income: $252MQ1'26Q2'26, Revenue: $3.0BQ2'26, Net income: $320MQ2'26Q3'26, Revenue: $3.1BQ3'26, Net income: $312MQ3'26$0$1B$2B$3B$4BQ4'22, Revenue: $2.3BQ4'22, Net income: $101MQ1'23, Revenue: $2.3BQ1'23, Net income: $202MQ1'23Q2'23, Revenue: $2.3BQ2'23, Net income: $235MQ3'23, Revenue: $2.3BQ3'23, Net income: $225MQ3'23Q4'23, Revenue: $2.3BQ4'23, Net income: $192MQ1'24, Revenue: $2.4BQ1'24, Net income: $194MQ1'24Q2'24, Revenue: $2.4BQ2'24, Net income: $229MQ3'24, Revenue: $2.5BQ3'24, Net income: $226MQ3'24Q4'24, Revenue: $2.6BQ4'24, Net income: $222MQ1'25, Revenue: $2.7BQ1'25, Net income: $220MQ1'25Q2'25, Revenue: $2.8BQ2'25, Net income: $282MQ3'25, Revenue: $2.8BQ3'25, Net income: $245MQ3'25Q4'25, Revenue: $2.8BQ4'25, Net income: $245MQ1'26, Revenue: $2.9BQ1'26, Net income: $252MQ1'26Q2'26, Revenue: $3.0BQ2'26, Net income: $320MQ3'26, Revenue: $3.1BQ3'26, Net income: $312MQ3'26

Net income losses drawn in red.

Free cash flow
−$200M$0$200M$400M$600MQ4'22, Free cash flow: $187MQ4'22Q1'23, Free cash flow: −$33MQ1'23Q2'23, Free cash flow: $340MQ2'23Q3'23, Free cash flow: $102MQ3'23Q4'23, Free cash flow: $455MQ4'23Q1'24, Free cash flow: $50MQ1'24Q2'24, Free cash flow: $268MQ2'24Q3'24, Free cash flow: $250MQ3'24Q4'24, Free cash flow: $341MQ4'24Q1'25, Free cash flow: $197MQ1'25Q2'25, Free cash flow: $436MQ2'25Q3'25, Free cash flow: $419MQ3'25Q4'25, Free cash flow: $307MQ4'25Q1'26, Free cash flow: $164MQ1'26Q2'26, Free cash flow: $459MQ2'26Q3'26, Free cash flow: $445MQ3'26−$200M$0$200M$400M$600MQ4'22, Free cash flow: $187MQ1'23, Free cash flow: −$33MQ1'23Q2'23, Free cash flow: $340MQ3'23, Free cash flow: $102MQ3'23Q4'23, Free cash flow: $455MQ1'24, Free cash flow: $50MQ1'24Q2'24, Free cash flow: $268MQ3'24, Free cash flow: $250MQ3'24Q4'24, Free cash flow: $341MQ1'25, Free cash flow: $197MQ1'25Q2'25, Free cash flow: $436MQ3'25, Free cash flow: $419MQ3'25Q4'25, Free cash flow: $307MQ1'26, Free cash flow: $164MQ1'26Q2'26, Free cash flow: $459MQ3'26, Free cash flow: $445MQ3'26

Operating cash flow less capital expenditures; negative quarters in red.

Cash and equivalents against long-term debtCash and equivalentsLong-term debt
$0$2B$4B$6BQ4'22, Cash and equivalents: $315MQ4'22, Long-term debt: $4.0BQ4'22Q1'23, Cash and equivalents: $175MQ1'23Q2'23, Cash and equivalents: $126MQ2'23Q3'23, Cash and equivalents: $143MQ3'23Q4'23, Cash and equivalents: $686MQ4'23, Long-term debt: $4.4BQ4'23Q1'24, Cash and equivalents: $474MQ1'24Q2'24, Cash and equivalents: $271MQ2'24Q3'24, Cash and equivalents: $764MQ3'24, Long-term debt: $5.6BQ3'24Q4'24, Cash and equivalents: $549MQ4'24, Long-term debt: $5.6BQ4'24Q1'25, Cash and equivalents: $188MQ1'25Q2'25, Cash and equivalents: $319MQ2'25Q3'25, Cash and equivalents: $432MQ3'25Q4'25, Cash and equivalents: $420MQ4'25, Long-term debt: $5.2BQ4'25Q1'26, Cash and equivalents: $393MQ1'26Q2'26, Cash and equivalents: $626MQ2'26, Long-term debt: $5.6BQ2'26Q3'26, Cash and equivalents: $797MQ3'26, Long-term debt: $5.5BQ3'26$0$2B$4B$6BQ4'22, Cash and equivalents: $315MQ4'22, Long-term debt: $4.0BQ1'23, Cash and equivalents: $175MQ1'23Q2'23, Cash and equivalents: $126MQ3'23, Cash and equivalents: $143MQ3'23Q4'23, Cash and equivalents: $686MQ4'23, Long-term debt: $4.4BQ1'24, Cash and equivalents: $474MQ1'24Q2'24, Cash and equivalents: $271MQ3'24, Cash and equivalents: $764MQ3'24, Long-term debt: $5.6BQ3'24Q4'24, Cash and equivalents: $549MQ4'24, Long-term debt: $5.6BQ1'25, Cash and equivalents: $188MQ1'25Q2'25, Cash and equivalents: $319MQ3'25, Cash and equivalents: $432MQ3'25Q4'25, Cash and equivalents: $420MQ4'25, Long-term debt: $5.2BQ1'26, Cash and equivalents: $393MQ1'26Q2'26, Cash and equivalents: $626MQ2'26, Long-term debt: $5.6BQ3'26, Cash and equivalents: $797MQ3'26, Long-term debt: $5.5BQ3'26

Positions at each quarter end, as filed; short-term investments are not included.

Income statement

Last eight quarters, newest first, through Q3 FY2026 filed October 23, 2026.

Quest Diagnostics Inc. income statement, quarterly
Millions of dollarsQ3 FY2026ended Sep 30, 2026filed Oct 23, 2026Q2 FY2026ended Jun 30, 2026filed Jul 23, 2026Q1 FY2026ended Mar 31, 2026filed Apr 22, 2026Q4 FY2025ended Dec 31, 2025filed Feb 26, 2026Q3 FY2025ended Sep 30, 2025filed Oct 21, 2025Q2 FY2025ended Jun 30, 2025filed Jul 23, 2025Q1 FY2025ended Mar 31, 2025filed Apr 23, 2025Q4 FY2024ended Dec 31, 2024filed Feb 20, 2025YoYQ3 FY2026vs Q3 FY2025
Revenue3,0973,0432,8952,8062,8162,7612,6522,621+10.0%
Cost of revenue2,0552,0161,9531,8961,8671,8181,7891,763+10.1%
Gross profit—————————
Research and development—————————
Selling, general and administrative523529504504501486476466+4.4%
Operating income479459399386386438346361+24.1%
Other income (expense)(63)(47)(65)(56)(58)(54)(70)(62)−8.6%
Pretax income416412334330328384276299+26.8%
Income tax9988748177975968+28.6%
Net income312320252245245282220222+27.3%
Diluted EPS ($)2.782.842.24—2.162.471.94—+28.7%
Diluted shares (millions)112112112—113113113——

Fourth quarters are the fiscal year less the first nine months when the filer reports no discrete fourth quarter, and are marked. Diluted EPS is never derived, so a derived quarter shows none. Italic figures are derived.

Balance sheet

Last eight quarters, newest first, through Q3 FY2026 filed October 23, 2026.

Quest Diagnostics Inc. balance sheet, quarterly
Millions of dollarsQ3 FY2026ended Sep 30, 2026filed Oct 23, 2026Q2 FY2026ended Jun 30, 2026filed Jul 23, 2026Q1 FY2026ended Mar 31, 2026filed Apr 22, 2026Q4 FY2025ended Dec 31, 2025filed Feb 26, 2026Q3 FY2025ended Sep 30, 2025filed Oct 21, 2025Q2 FY2025ended Jun 30, 2025filed Jul 23, 2025Q1 FY2025ended Mar 31, 2025filed Apr 23, 2025Q4 FY2024ended Dec 31, 2024filed Feb 20, 2025YoYQ3 FY2026vs Q3 FY2025
Cash and equivalents797626393420432319188549+84.5%
Short-term investments—————————
Total current assets3,1172,8442,5662,3782,4072,1982,0752,392+29.5%
Total assets17,22116,93916,67316,22516,19715,96915,79716,153+6.3%
Total current liabilities1,8341,7882,1772,2782,1342,0241,4412,169−14.1%
Long-term debt5,5405,632—5,167———5,615—
Total liabilities—————————
Stockholders’ equity7,6327,5167,3667,1707,2587,2286,9296,778+5.2%
Shares outstanding (millions)110110111110111112112111—

Positions at each period end. Nothing on this statement is derived. Long-term debt is the filed noncurrent line only; no total-debt composite is constructed across filers. Italic figures are derived.

Cash flow statement

Last eight quarters, newest first, through Q3 FY2026 filed October 23, 2026.

Quest Diagnostics Inc. cash flow statement, quarterly
Millions of dollarsQ3 FY2026ended Sep 30, 2026filed Oct 23, 2026Q2 FY2026ended Jun 30, 2026filed Jul 23, 2026Q1 FY2026ended Mar 31, 2026filed Apr 22, 2026Q4 FY2025ended Dec 31, 2025filed Feb 26, 2026Q3 FY2025ended Sep 30, 2025filed Oct 21, 2025Q2 FY2025ended Jun 30, 2025filed Jul 23, 2025Q1 FY2025ended Mar 31, 2025filed Apr 23, 2025Q4 FY2024ended Dec 31, 2024filed Feb 20, 2025YoYQ3 FY2026vs Q3 FY2025
Operating cash flow611597278465563544314464+8.5%
Capital expenditures166138114158144108117123+15.3%
Free cash flow (CFO − capex)445459164307419436197341+6.2%
Depreciation and amortization147146147145142143140135+3.5%
Share repurchases150——300150——1510.0%
Dividends paid9596889089908484+6.7%

10-Qs file cash flows as year-to-date totals, so quarterly figures are differenced from consecutive filings and marked. Free cash flow is operating cash flow less capital expenditures, computed from the two filed lines. Italic figures are derived.

Annual statements

Every fiscal year filed, newest first, through FY2025 filed February 26, 2026.

Income statement

Quest Diagnostics Inc. income statement, annual
Millions of dollarsFY2025ended Dec 31, 2025filed Feb 26, 2026FY2024ended Dec 31, 2024filed Feb 20, 2025FY2023ended Dec 31, 2023filed Feb 22, 2024FY2022ended Dec 31, 2022filed Feb 21, 2023FY2021ended Dec 31, 2021filed Feb 28, 2022FY2020ended Dec 31, 2020filed Feb 22, 2021FY2019ended Dec 31, 2019filed Feb 20, 2020FY2018ended Dec 31, 2018filed Feb 21, 2019FY2017ended Dec 31, 2017filed Feb 23, 2018FY2016ended Dec 31, 2016filed Feb 22, 2017FY2015ended Dec 31, 2015filed Feb 26, 2016FY2014ended Dec 31, 2014filed Feb 24, 2015FY2013ended Dec 31, 2013filed Feb 18, 2014FY2012ended Dec 31, 2012filed Feb 27, 2013FY2011ended Dec 31, 2011filed Feb 16, 2012FY2010ended Dec 31, 2010filed Feb 16, 2011FY2009ended Dec 31, 2009filed Feb 17, 2010FY2008ended Dec 31, 2008filed Jul 28, 2009FY2007ended Dec 31, 2007filed Jul 28, 2009
Revenue11,0359,8729,2529,88310,7889,4377,7267,5317,4027,2147,4937,4357,1467,3837,3927,2607,4557,2496,705
Cost of revenue7,3706,6286,1996,4506,5795,8045,0374,9264,7194,6164,6574,6374,3264,3654,3634,2764,3214,2563,970
Gross profit—————3,6332,6892,6052,6832,8992,8362,7982,8203,0183,0293,0523,134——
Research and development———————————————————
Selling, general and administrative1,9671,7701,6421,8741,7271,5501,4571,4241,4431,3801,6791,7281,7041,7451,7431,6591,7481,7371,613
Operating income1,5561,3461,2621,4282,3811,9711,2311,1011,1651,2771,3999831,4751,2019871,2841,3591,2221,091
Other income (expense)(238)(171)(132)(193)218(87)(155)(175)(135)(191)(296)(160)(151)(133)(138)(109)(131)(172)(152)
Pretax income1,3181,1751,1301,2352,5991,8841,0769261,0301,0861,1038231,324—8561,1841,2281,051—
Income tax314273248264597460247182241429373262500402355430460387359
Net income9928718549461,9951,431858736772645709556849556471721729581340
Diluted EPS ($)8.757.697.497.9715.5510.476.285.295.504.514.873.815.543.462.924.053.872.961.74
Diluted shares (millions)113113113118128136136139140142145145153160160177188196—

Balance sheet

Quest Diagnostics Inc. balance sheet, annual
Millions of dollarsFY2025ended Dec 31, 2025filed Feb 26, 2026FY2024ended Dec 31, 2024filed Feb 20, 2025FY2023ended Dec 31, 2023filed Feb 22, 2024FY2022ended Dec 31, 2022filed Feb 21, 2023FY2021ended Dec 31, 2021filed Feb 28, 2022FY2020ended Dec 31, 2020filed Feb 22, 2021FY2019ended Dec 31, 2019filed Feb 20, 2020FY2018ended Dec 31, 2018filed Feb 21, 2019FY2017ended Dec 31, 2017filed Feb 23, 2018FY2016ended Dec 31, 2016filed Feb 22, 2017FY2015ended Dec 31, 2015filed Feb 26, 2016FY2014ended Dec 31, 2014filed Feb 24, 2015FY2013ended Dec 31, 2013filed Feb 18, 2014FY2012ended Dec 31, 2012filed Feb 27, 2013FY2011ended Dec 31, 2011filed Feb 16, 2012FY2010ended Dec 31, 2010filed Feb 16, 2011FY2009ended Dec 31, 2009filed Feb 17, 2010FY2008ended Dec 31, 2008filed Jul 28, 2009FY2007ended Dec 31, 2007filed Jul 28, 2009
Cash and equivalents4205496863158721,1581,192135137359133192187296165449534254168
Short-term investments———————————————————
Total current assets2,3782,3922,3721,8982,7413,0582,4901,3901,3061,5311,5011,6031,3831,5611,4011,6051,6791,497—
Total assets16,22516,15314,02212,83713,61114,02612,84311,00310,50310,1009,9629,8578,9489,2849,3138,5288,5648,404—
Total current liabilities2,2782,1691,8151,5511,7531,7761,9901,4851,0579811,1731,7091,1321,0481,5611,2141,0591,225—
Long-term debt5,1675,6154,4103,9784,0104,0133,9663,4293,7483,7283,4923,2243,1203,3643,9402,641———
Total liabilities———————————————————
Stockholders’ equity7,1706,7786,3075,8936,4446,7595,6415,2164,9214,6284,6844,3013,9484,1633,6934,0333,9903,605—
Shares outstanding (millions)110111111111119133133134136137143144144158158171179——

Cash flow statement

Quest Diagnostics Inc. cash flow statement, annual
Millions of dollarsFY2025ended Dec 31, 2025filed Feb 26, 2026FY2024ended Dec 31, 2024filed Feb 20, 2025FY2023ended Dec 31, 2023filed Feb 22, 2024FY2022ended Dec 31, 2022filed Feb 21, 2023FY2021ended Dec 31, 2021filed Feb 28, 2022FY2020ended Dec 31, 2020filed Feb 22, 2021FY2019ended Dec 31, 2019filed Feb 20, 2020FY2018ended Dec 31, 2018filed Feb 21, 2019FY2017ended Dec 31, 2017filed Feb 23, 2018FY2016ended Dec 31, 2016filed Feb 22, 2017FY2015ended Dec 31, 2015filed Feb 26, 2016FY2014ended Dec 31, 2014filed Feb 24, 2015FY2013ended Dec 31, 2013filed Feb 18, 2014FY2012ended Dec 31, 2012filed Feb 27, 2013FY2011ended Dec 31, 2011filed Feb 16, 2012FY2010ended Dec 31, 2010filed Feb 16, 2011FY2009ended Dec 31, 2009filed Feb 17, 2010FY2008ended Dec 31, 2008filed Jul 28, 2009FY2007ended Dec 31, 2007filed Jul 28, 2009
Operating cash flow1,8861,3341,2721,7182,2332,0051,2431,2001,1751,1168219446521,1878951,1189971,063927
Capital expenditures527425408404403418400383252293263308231182161205167213219
Free cash flow (CFO − capex)1,3599098641,3141,8301,5878438179238235586364211,005734913830850708
Depreciation and amortization570493439437408361329309270249304314283287281254257265238
Share repurchases4501512751,4082,1993253533224655902241321,037200935750500254146
Dividends paid3533313143053092972862662472232121871851086571757877

Insider activity

Form 4 filings by officers, directors and 10% owners, November 1, 2024 to November 1, 2026. Only open-market purchases and sales count as buys and sells; awards, exercises, tax withholding and gifts are listed in grey and never counted.

Bought, three months
$0
0 purchases by 0 insiders; officers and directors $0
Sold, three months
$8M
5 sales by 3 insiders; officers and directors $8M
Bought, twelve months
$0
0 purchases by 0 insiders; officers and directors $0
Sold, twelve months
$37M
30 sales by 8 insiders; officers and directors $37M

The last 25 transactions

TradedInsiderRoleTransactionSharesPriceValueHeld afterFiled
Oct 26, 2026Pfeiffer Gary MDirectoropen-market sale10b5-11,203$243.00$292K29,802Oct 28, 2026
Oct 21, 2026Carter Robert BDirectorsmall acquisition10$235.93$2K3,874Oct 23, 2026
Oct 21, 2026Samad SamExecutive Vice President & CFOaward90$235.94$21K33,568Oct 23, 2026
Oct 21, 2026Gregg Vicky BDirectoraward63$235.94$15K18,449Oct 23, 2026
Oct 21, 2026Kuppusamy KarthikSVP, Clinical Solutionssmall acquisition33$235.94$8K13,619Oct 23, 2026
Oct 21, 2026Lassiter Wright IIIDirectorsmall acquisition6$235.96$1K10,329Oct 23, 2026
Oct 21, 2026Plewman PatrickSVP for Diagnostic Servicessmall acquisition41$235.94$10K15,334Oct 23, 2026
Oct 21, 2026Main Timothy LDirectorsmall acquisition18$235.94$4K22,478Oct 23, 2026
Oct 21, 2026Delaney Mark ESVP & Chief Commercial Officersmall acquisition25$235.94$6K10,360Oct 23, 2026
Sep 1, 2026Davis J. E.CEO and President, Directoropen-market sale10b5-110,000$242.72$2M122,423Sep 3, 2026
Aug 28, 2026Prevoznik Michael ESVP & General Counseloption exercise22,677$112.17$3M60,234Aug 31, 2026
Aug 28, 2026Prevoznik Michael ESVP & General Counselopen-market sale10b5-116,010$242.88$4M44,224Aug 31, 2026
Aug 28, 2026Prevoznik Michael ESVP & General Counselopen-market sale10b5-16,237$243.63$2M37,987Aug 31, 2026
Aug 28, 2026Prevoznik Michael ESVP & General Counselopen-market sale10b5-1430$244.51$105K37,557Aug 31, 2026
Aug 28, 2026Prevoznik Michael ESVP & General Counselgift1,000$0.00—36,557Aug 31, 2026
Jul 28, 2026Delaney Mark ESVP & Chief Commercial Officeropen-market sale10b5-11,600$235.18$376K10,335Jul 29, 2026
Jul 22, 2026Kuppusamy KarthikSVP, Clinical Solutionssmall acquisition37$206.81$8K13,557Jul 27, 2026
Jul 22, 2026Carter Robert BDirectorsmall acquisition11$206.80$2K3,864Jul 27, 2026
Jul 22, 2026Gregg Vicky BDirectoraward72$206.81$15K18,386Jul 27, 2026
Jul 22, 2026Plewman PatrickSVP for Diagnostic Servicessmall acquisition46$206.81$10K15,293Jul 27, 2026
Jul 22, 2026Main Timothy LDirectorsmall acquisition21$206.81$4K22,460Jul 27, 2026
Jul 22, 2026Samad SamExecutive Vice President & CFOaward102$206.81$21K33,478Jul 27, 2026
Jul 22, 2026Lassiter Wright IIIDirectorsmall acquisition6$206.81$1K10,323Jul 27, 2026
Jul 22, 2026Delaney Mark ESVP & Chief Commercial Officersmall acquisition34$206.81$7K11,935Jul 27, 2026
Jun 4, 2026Kuppusamy KarthikSVP, Clinical Solutionsoption exercise3,320$127.72$424K16,830Jun 8, 2026

Full insider history for Quest Diagnostics Inc., or insider activity across all companies. A record of filings, not a recommendation.

Sources

Fiscal year ends in month 12; periods are labeled with the issuer's own fiscal calendar. Values are as most recently filed (restatements apply; per-share values are on current split basis per the connector's split table, flagged in adjusted). Flow items flagged in `derived` were computed (Q4 = FY − nine months; quarterly cash flow differenced from year-to-date filings) rather than read from a filing. `reconciliation.repaired` lists periods where a full-year figure was filed in a quarter slot: that row was dropped and the quarter rebuilt from the annual figure. `reconciliation.quarantined` lists periods where four filed quarters do not sum to the filed year — those quarterly values are withheld, so a blank there is a withholding rather than an absence of reporting.

Filer
Quest Diagnostics Inc, CIK 1022079 on EDGAR
Extract generated
October 26, 2026
Withheld
3 line-years whose four quarters do not sum to the filed year: revenue FY2010, income tax FY2014, revenue FY2016
Repaired
none
XBRL concepts behind each line

Income statement

Revenue: RevenueFromContractWithCustomerExcludingAssessedTax, SalesRevenueNet
Cost of revenue: CostOfRevenue
Gross profit: GrossProfit
Research and development: not filed
Selling, general and administrative: SellingGeneralAndAdministrativeExpense
Operating income: OperatingIncomeLoss
Other income (expense): NonoperatingIncomeExpense
Pretax income: IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest, IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
Income tax: IncomeTaxExpenseBenefit
Net income: NetIncomeLoss
Diluted EPS ($): EarningsPerShareDiluted
Diluted shares (millions): WeightedAverageNumberOfDilutedSharesOutstanding

Balance sheet

Cash and equivalents: CashAndCashEquivalentsAtCarryingValue
Short-term investments: not filed
Total current assets: AssetsCurrent
Total assets: Assets
Total current liabilities: LiabilitiesCurrent
Long-term debt: LongTermDebt, LongTermDebtNoncurrent
Total liabilities: not filed
Stockholders’ equity: StockholdersEquity
Shares outstanding (millions): dei:EntityCommonStockSharesOutstanding

Cash flow statement

Operating cash flow: NetCashProvidedByUsedInOperatingActivities
Capital expenditures: PaymentsToAcquirePropertyPlantAndEquipment
Free cash flow (CFO − capex): not filed
Depreciation and amortization: DepreciationDepletionAndAmortization
Share repurchases: PaymentsForRepurchaseOfCommonStock
Dividends paid: PaymentsOfDividendsCommonStock

The data

The statements on this page as files, generated October 26, 2026.

JSON file
/data/financials/DGX.json